Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

This study, through a clinical controlled trial, compared the one-year, three-year, and five-year overall survival rates between patients receiving a treatment plan guided by organoid drug sensitivity and those receiving conventional empirical treatment. Univariate Kaplan-Meier survival analysis was used to compare the differences in overall survival between the two groups. The study aimed to evaluate the application value of tumor organoid drug sensitivity testing in guiding neoadjuvant chemotherapy for bladder cancer.

NCT Number	NCT07379281
Lead Sponsor	Qilu Hospital of Shandong University Collaborators: The Second Hospital of Shandong University, Qianfoshan Hospital, Shandong Provincial Hospital, Shandong Province Third hospital, Taian City Central Hospital, Weifang People's Hospital, Binzhou Medical University, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Liaocheng People's Hospital, Linyi People's Hospital, Yantai Yuhuangding Hospital, Zibo Central Hospital, Dezhou Hospital Qilu Hospital of Shandong University, Zaozhuang Municipal Hospital, Qilu Hospital of Shandong University (Qingdao)
Conditions	Bladder Cancer
Enrollment	254 participants
Start Date	2025-01-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-30